Clinical trial
Selinexor in Combination With Immunomodulator to Treat Relapsed/Refractory Multiple Myeloma Patients
NCT04941937 is registered in ClinicalTrials.gov with Juan Du as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Selinexor in Combination With Immunomodulator to Treat Relapsed/Refractory Multiple Myeloma Patients
- Lead sponsor
- Juan Du
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- January 27, 2022
- Completion date
- December 30, 2025
- Enrollment
- 90 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.